Toxic nephropathies

Current Opinion in Pediatrics

Volumn 9, Issue 2, 1997, Pages 166-169

  Springate, James E ^a  

^a CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CEFOTAXIME; CEPHALOSPORIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IFOSFAMIDE; LORACARBEF; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLIN G; TRIMETHOPRIM; VALPROIC ACID;

ANALGESIC NEPHROPATHY; CHILDHOOD CANCER; FEVER; HEMORRHAGIC CYSTITIS; HUMAN; HYPERKALEMIA; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; SHORT SURVEY;

ANALGESICS; ANALGESICS, NON-NARCOTIC; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; IFOSFAMIDE; KIDNEY DISEASES;

EID: 0030923676     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199704000-00009     Document Type: Short Survey

References (45)

1. Skinner R, Sharkey I, Pearson A, Craft A: Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993, 11:173-190.
2. 2-microglobulinuria appears to identify patients destined to develop chronic renal disease.
3. Skinner R, Pearson A, English M, Price L, Wyllie R, Coulthard M, Craft A: Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996, 348:578-580.
4. Prasad V, Lewis I, Aparicio S, Heney D, Hale J, Bailey C, Kinsey S: Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996, 27:149-155.
5. Womer R: Ifosfamide and paediatrics: should this marriage be saved? Eur J Cancer 1996, 32A:1100-1101.
6. Springate J, Van Liew J: Nephrotoxicity of ifosfamide in rats. J Appl Toxicol 1995, 15:399-402.
7. Nissim I, Weinberg J: Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int 1996, 49:684-695.
8. Sood C, O'Brien P: 2-chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Br J Cancer 1996, 74:3287-8293.
9. Zamlauski-Tucker M, Morris M, Springate J: Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 1994, 129:170-175.
10. 1). Renal Physiol Biochem 1995, 18:118-127.
11. Boddy A, English M, Pearson A, Idle J, Skinner R: Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer 1996, 32A:1179-1184. This thorough clinical investigation examines the hypothesis that individual variations in systemic ifosfamide metabolism are associated with a higher risk of nephropathy. Results show a negative correlation between production of dechloroethylated ifosfamide metabolites and renal injury. The authors speculate that differences in renal rather than hepatic drug metabolism may be responsible for nephrotoxicity.
12. Lieberthal W, Triaca V, Levine J: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996, 270:F700-F708.
13. Hanigan M, Gallagher B, Taylor P: Cisplatin nephrotoxicity: inhibition of γ-glutemyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney. Am J Obstet Gynecol 1996, 175:270-274. This study convincingly demonstrates that inhibition of γ-glutamyl transpeptidase prevents cisplatin nephrotoxicity without altering kidney platinum uptake or content. It is an excellent example of potential glutathione conjugate-mediated toxicity and of the importance of considering renal metabolism when evaluating drug-induced nephrotoxicity.
14. Yarbro J, Bornstein R, Mastrangelo M: Applications of amifostine in cancer treatment. Semin Oncol 1996, 23(suppl 8):1-99.
15. Henrich W, Agodoa L, Barrett B, Bennett W, Blantz R, Buckalew V, D'Agati V, DeBroe M, Duggin G, Eknoyan G, Elseviers M, Gomez A, Matzke G, Porter G, Sabatini S, Stoff J, Striker G, Winchester J: Analgesics and the kidney: summary and recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis 1996, 27:162-165. This position paper provides concise, practical recommendations about analgesic-related renal disease and the appropriate use of aspirin, acetaminophen, and NSAIDs.
16. Aronson M, Blantz R, Ettenger R, Neilson E, Peura D, Shapiro S, Suki W: Reassessment of the Renal Effects of Analgesics. Springfield: Scientific Therapeutics Information, Inc.; 1995.
17. Bennett W, Henrich W, Stoff J: The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996, 28:S56-S62. This review is a useful summary of basic science and clinical information relating to adverse renal effects of nonsteroidal anti-inflammatory medications.
18. Blowey D, Bendavid S, Koren G: Interactions of drugs with the developing kidney. Pediatr Clin North Am 1995, 42:1415-1431. This article is an excellent summary of the effects of a variety of medications on renal function in infants and children.
19. Buck M, Norwood V: Ketorolac-induced acute renal failure in a previously healthy adolescent. Pediatrics 1996, 98:294-296.
20. Heijden A, Gubler M: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1995, 5:675.
21. Spangler R: Cyclooxygenase 1 and 2 in rheumatic disease - implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996, 26:435-446.
22. Engelhardt G, Bogel R, Schnitzer C, Utzman R: Meloxican - influence on arachidonic acid metabolism. Biochem Pharmacol 1996, 51:21-38.
23. Dinchuck J, Car B, Focht R, Johnston J, Jaffee B, Covington M, Contel N, Eng V, Collins R, Czerniak P, Gorry S, Trzaskos J: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406-409.
24. Blakely P, McDonald B: Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol 1995, 6:48-53.
25. Blantz R: Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis 1996, 28:S3-S6. This brief review discusses the nephrotoxic potential of large doses of acetaminophen as well as the safety of therapeutic doses.
26. Sawaya B, Briggs J, Schnermann J: Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995, 6:154-164. The authors provide an excellent summary of laboratory and clinical information relating to the problem of amphotericin B renal injury.
27. Llanos A, Cieza J, Bernardo J: Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991, 40:302-308.
28. Sharkey P, Graybill J, Johnson E, Hausrath S, Pollard R, Mildvan D, Eng R, Pottage J, Wolf J, Gupta R, Lee L, Gordon D: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:315-321.
29. Pascual B, Ayestaran A, Montoro J, Oliveras J, Estibalez A, Julia A, Lopez A: Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995, 29:1197-1201.
30. Kline S, Larsen T, Fieber L, Fishbach R, Greenwood M, Harris R, Kline M, Tennican P, Janoff E: Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995, 21:1154-1158.
31. Moestrup S, Ciu S, Varum C, Bregengard S, Norris K, Gliemann J, Christensen E: Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995, 96:1404-1413. Glycoprotein 330 is concentrated in the apical region of proximal tubule cells. It was initially described as a major target antigen in Heymann nephritis, an experimental model of antibody-mediated membranous glomerulonephritis. It now appears that this glycoprotein is a drug receptor that mediates cell uptake and toxicity of aminoglycoside.
32. Gordjani N, Burghard R, Muller D, Mathai H, Mergehenn G, Leititis J, Brandis M: Urinary excretion of adenosine deaminase binding protein In neonates treated with tobramycin. Pediatr Nephrol 1995, 9:419-422.
33. 1-microglobulin. Pediatr Nephrol 1996, 10:645-647.
34. Deamer R, Dial L: The evolution of aminoglycoside therapy: a single daily dose. Am Fam Physician 1996, 53:1782-1786. A thought-provoking review of current aminoglycoside dosing regimens that convincingly illustrates the utility of once-daily administration.
35. Hatala R, Dinh T, Cook D: Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996, 124:717-724.
36. Kasama R, Sorbello A: Renal and electrolyte complications associated with antibiotic therapy. Am Fam Physician 1996, 53:227-232.
37. Thieme R, Caldwell S, Lum G: Acute interstitial nephritis associated with loracarbef therapy. J Pediatr 1995, 127:997-1000.
38. Alshohaib S, Satti M, Abunijem Z: Acute interstitial nephritis due to cefotaxime. Nephron 1996, 73:725.
39. Kahn S: Acute interstitial nephritis associated with nitrofurantoin. Lancet 1996, 348:1177-1178.
40. Fleury D, Storkebaum H, Mougenot B, Bridoux F, Gobert P, Lemaitre V, Vanhille P: Acute interstitial nephritis due to omeprazole. Clin Nephrol 44:129.
41. Fukuda Y, Watanabe H, Ohtomo Y, Yabuta K: Immunologically mediated tubulointerstitial nephritis caused by valproate therapy. Nephron 72:328-329.
42. Alappan R, Perazella M, Buller G: Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996, 124:316-320.
43. Perazella M, Mahnenamith R: Trimethoprim-sulfamethoxazole - hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996, 48:187-192. This clinically oriented review alerts health care providers to an important under-estimated side effect of trimethoprim.
44. Eiamong S, Kurtzman N, Sabatini S: Studies on the mechanism of trimethoprim-induced hyperkalemla. Kidney Int 1996, 49:1372-1378.
45. Schreiber M, Schlanger L, Chan C, Lessanpezeshki M, Halperin M, Patnaik A, Ling B, Kleyman T: Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int 1996, 49:82-87.